the aid library

LIST OPTIONS

Filter

10536

Technical series on adapting to climate-sensitive health impacts: Diarrhoeal diseases

World Health Organization WHO (2023) C_WHO

This guide presents a basis for understanding how diarrhoeal diseases are currently influenced by climate and weather, and may be further exacerbated by climate change. It is a technical guide on how to conduct a Vulnerability & Adaptation assessment for diarrhoeal diseases and climate change, and p... more

WHO mid-term programmatic and financial report for 2016-2017 including audited financial statements for 2016

World Health Organisation (WHO) (2017) C_WHO

In an ambitious new era for health development under the 2030 Agenda for Sustainable Development, WHO and its partners have a solid foundation of success on which to build. Health plays a fundamental role in development and is the central focus of Sustainable Development Goal 3, “Ensure healthy ... more

Responding to communicable and noncommunicable diseases: progress report 2020-2022

World Health Organization WHO (2023) C_WHO

Significant progress has been made in the eradication of three priority diseases in the African Region, as a result of extensive collaboration between the Regional Office, WHO country offices and countries. For example, in August 2020, the region was certified free of wild poliovirus. In the area of... more

Cholera Outbreak Response Field Manual (October 2019)

WASH Cluster; World Health Organization WHO (2023) CC

The response to a cholera outbreak must focus on limiting mortality and reducing the spread of the disease. It should be comprehensive and multisectoral, including epidemiology, case management, water, sanitation and hygiene, logistics, community engagement and risk communication. All efforts must b... more

Download (116)

View PDF (135)

Tracking Official Development Assistance for Reproductive Health in Conflict-Affected Countries

Patel P.; Roberts B.; Gury S. et al. PLOS Medecine (2009) CC

Reproductive health needs are particularly acute in countries affected by armed conflict. Reliable information on aid investment for reproductive health in these countries is essential for improving the efficiency and effectiveness of aid. The purpose of this study was to analyse official developm... more

Download (287)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (195)

View PDF (157)

A Guide to Inclusive Education 2023
recommended

Jesuit Refugee Service (2023) CC

Refugee children with disabilities experience a reality of exclusion and marginalisation that makes them among the most vulnerable displaced persons in the world. Excluded from participation in social activities and access to school, not only because of their disability, but especially because of so... more

CVD Advocacy Toolkit: The Road to 2018

Markbreiter, J.; Buckley, P. World Heart Federation (2016) CC

The World Heart Federation (WHF) has been advocating globally for stronger legislation and policy regarding cardiovascular disease (CVD) for many years. Now, as focus shifts from global to national progress, we call on members and colleagues to advocate for greater action on CVD in your local setti... more

External Link

Advocation for Cholesterol control: A world heard federation toolkit

World Heart Federation (2022) CC

The World Heart Federation (WHF) is a leading global advocate for stronger legislation and policies regarding cardiovascular disease (CVD) and its risk factors, including raised cholesterol. The present Cholesterol Advocacy Toolkit 2022 provides WHF member organizations with information as well as p... more

External Link

The Treatment of Heart Failure with Reduced Ejection Fraction

Berliner, D.; Hänselmann, A.; Bauersachs, J. Deutsches Ärzteblatt International (2020) CC

Background Chronic congestive heart failure is a common condition that, if untreated, markedly impairs the quality of life and is associated with a high risk of recurrent hospitalization and death. Methods This review is based on articles retrieved by a selective search in PubMed, as well as on r... more

Analysis of Pandemic Preparedness and Response (PPR) architecture, financing needs, gaps and mechanisms

World Bank (2022) CC

A global Pandemic, Preparedness and Response (RRR) architecture

Global Appeal 2021 update

UNHCR The UN Refugee Agency (2021) CC

The Global Appeal provides updated information for government, private donors, partners and other readers interested in UNHCR's priorities and budgeted activities for 2021 to protect and improve the lives of tens of millions of people of concern (refugees, internally displaced people, stateless pers... more

Download (113)

View PDF (120)

Development Co-operation Report 2020

OECD (2020) CC

The annual Development Co-operation Report brings new evidence, analysis and ideas on sustainable development to members of the OECD Development Assistance Committee (DAC) and the international community more broadly. The objectives are to promote best practices and innovation in development co-ope... more

External Link

Environmental Determinants of Cardiovascular Disease

Bhatnagar, A. Circulation Research (2018) CC

Many features of the environment have been found to exert an important influence on cardiovascular disease (CVD) risk, progression, and severity. Changes in the environment due to migration to different geographic locations, modifications in lifestyle choices, and shifts in social policies and cultu... more

ESC Clinical Practice Guidelines on Cardiovascular Disease Prevention in Clinical Practice: What Patients Need to Know

European Society of Cardiology (2022) CC

This guide for patients aims to provide you with an overview of the latest evidence-based recommendations for the prevention of cardiovascular disease. In particular, it should help you to understand: • how cardiovascular disease risk is assessed • the importance of lifestyle modifications for... more

Pediatric Oncology nursing practice in Latin America and the Carribbean

World Health Organization WHO (2023) C_WHO

This technical report has been developed within the framework of the WHO Global Initiative for Childhood Cancer. Its goal is to improve the situation of children and adolescents with cancer worldwide, giving them the best chances of survival, living a full life and, above all, enjoying quality of ... more

External Link

Epidemiology of Peripheral Artery Disease and Polyvascular Disease

Aday A.W.; Matsushita, K. Circulation Research (2021) CC

Atherosclerotic lower-extremity peripheral artery disease (PAD) is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects more than 230 million people worldwide. Traditional cardiovascular risk factors, including advanced age, smoking, and diabetes, are ... more

Download (71)

View PDF (52)

Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes

Park, J.J. Diabetes & Metabolism Journal (2021) CC

The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients wit... more

Download (143)

View PDF (134)

Laboratory manual for yellow fever
recommended

World Health Organization WHO (2024) C_WHO

This WHO laboratory manual provides the most up to date methods and procedures for the laboratory identification of yellow fever virus infection in humans. It provides guidance on the establishment and maintenance of an effective laboratory providing routine surveillance testing for yellow fever, wh... more

Download (270)

View PDF (141)

WHO Emergency Response Framework - Internal WHO procedures - Second Edition

World Health Organization WHO (2024) C_WHO

The ERF provides WHO staff with essential guidance on how the Organization manages the assessment, grading and response to public health events and emergencies with health consequences, in support of Member States and affected communities. The ERF adopts an all-hazards approach and it is therefore a... more

A Guide to Inclusive Education 2023 recommended

Laboratory manual for yellow fever recommended

A Guide to Inclusive Education 2023
recommended

Laboratory manual for yellow fever
recommended